GlassScriptPhysician profile
Derrick A Williams
NPI 1083815393
$1,324.65
in general payments reported to CMS, 2019-2025
27 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $242 · 2021: $98.87 · 2022: $28.66 · 2023: $136 · 2024: $130 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $145.29 | 2020 | |
| Abbvie INC. | $130.08 | 2021-2025 | Linzess, Viberzi, Creon |
| Amgen INC. | $116.62 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $106.20 | 2019-2025 | |
| Lilly USA, LLC | $100.37 | 2019-2024 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $92.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $70.60 | 2019-2025 | Breztri |
| Novo Nordisk INC | $58.36 | 2019-2023 | Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $43.84 | 2019-2020 | |
| Boston Scientific Corporation | $38.97 | 2025 | Watchman Flx, Wavewriter Alpha Prime 16 |
| E.R. Squibb & Sons, L.L.C. | $35.49 | 2019-2020 | |
| Terumo Medical Corporation | $30.39 | 2024 | Azur Cx Detachable |
| Stryker Corporation | $30.35 | 2025 | Procuity |
| Merck Sharp & Dohme LLC | $28.27 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.23 | 2019 | |
| Dexcom, INC. | $20.42 | 2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $20.02 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.56 | 2019 | |
| Eisai INC. | $19.16 | 2025 | |
| Medtronic, INC. | $18.94 | 2023 | Intellis Adaptivestim |
| Sanofi Pasteur INC. | $15.24 | 2020 | |
| Phathom Pharmaceuticals, INC. | $14.85 | 2025 | Voquezna |
| Astellas Pharma US INC | $14.20 | 2024 | Veozah |
| Allergan, INC. | $13.23 | 2019 | |
| Abbott Laboratories | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.